Zentalis Pharmaceuticals, Inc.ZNTLNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank43
3Y CAGR-5.4%
5Y CAGR+10.1%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-5.4%/yr
vs +75.8%/yr prior
5Y CAGR
+10.1%/yr
Recent deceleration
Acceleration
-81.2pp
Decelerating
Percentile
P43
Within normal range
vs 5Y Ago
1.6x
Solid growth
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $192.13M | -25.7% |
| 2024 | $258.62M | -13.7% |
| 2023 | $299.51M | +31.8% |
| 2022 | $227.29M | +5.0% |
| 2021 | $216.54M | +82.3% |
| 2020 | $118.79M | +153.6% |
| 2019 | $46.84M | +96.9% |
| 2018 | $23.80M | - |